Curis Inc (CRIS)
15.60
+0.33
(+2.16%)
USD |
NASDAQ |
Apr 17, 15:42
Curis Enterprise Value: 33.67M for April 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 16, 2024 | 33.67M |
April 15, 2024 | 29.48M |
April 12, 2024 | 33.73M |
April 11, 2024 | 37.38M |
April 10, 2024 | 33.73M |
April 09, 2024 | 35.50M |
April 08, 2024 | 40.92M |
April 05, 2024 | 42.69M |
April 04, 2024 | 38.03M |
April 03, 2024 | 22.65M |
April 02, 2024 | 16.28M |
April 01, 2024 | 18.40M |
March 28, 2024 | 7.735M |
March 27, 2024 | 7.735M |
March 26, 2024 | 3.138M |
March 25, 2024 | 7.499M |
March 22, 2024 | 7.322M |
March 21, 2024 | 7.499M |
March 20, 2024 | 4.552M |
March 19, 2024 | 3.904M |
March 18, 2024 | 3.491M |
March 15, 2024 | 4.375M |
March 14, 2024 | 3.727M |
March 13, 2024 | 4.022M |
March 12, 2024 | 2.725M |
Date | Value |
---|---|
March 11, 2024 | 4.670M |
March 08, 2024 | 5.554M |
March 07, 2024 | 2.489M |
March 06, 2024 | 1.192M |
March 05, 2024 | 4.375M |
March 04, 2024 | 0.8623M |
March 01, 2024 | 3.020M |
February 29, 2024 | 3.727M |
February 28, 2024 | 1.251M |
February 27, 2024 | 2.666M |
February 26, 2024 | 1.310M |
February 23, 2024 | -0.2811M |
February 22, 2024 | 1.605M |
February 21, 2024 | 4.198M |
February 20, 2024 | 3.432M |
February 16, 2024 | 5.495M |
February 15, 2024 | 3.904M |
February 14, 2024 | 4.316M |
February 13, 2024 | 3.432M |
February 12, 2024 | 6.851M |
February 09, 2024 | 5.024M |
February 08, 2024 | 6.438M |
February 07, 2024 | -0.9884M |
February 06, 2024 | -0.8116M |
February 05, 2024 | -6.293M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-55.89M
Minimum
May 24 2022
1.334B
Maximum
May 12 2021
154.96M
Average
24.46M
Median
Enterprise Value Benchmarks
Kura Oncology Inc | 1.001B |
AIM ImmunoTech Inc | 12.33M |
Perspective Therapeutics Inc | 849.38M |
Protalix BioTherapeutics Inc | 58.97M |
Armata Pharmaceuticals Inc | 184.45M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -11.71M |
Revenue (Quarterly) | 2.696M |
Total Expenses (Quarterly) | 14.90M |
EPS Diluted (Quarterly) | -2.03 |
Gross Profit Margin (Quarterly) | 98.00% |
Profit Margin (Quarterly) | -434.4% |
Earnings Yield | -57.44% |
Normalized Earnings Yield | -57.44 |